Suggestions
Morgan Cheatham
Vice President at Bessemer Venture Partners focused on healthcare and life sciences
Morgan Cheatham is a Vice President at Bessemer Venture Partners, a prominent global venture capital firm with over $9 billion in assets under management. He specializes in investments within the healthcare and life sciences sectors, focusing on companies that leverage unique datasets and computational methods to enhance patient care across various stages of development, from pre-seed to growth.123
Cheatham's background includes a Bachelor of Science in Neuroeconomics from Brown University, where he graduated magna cum laude. He is currently pursuing his medical degree at The Warren Alpert Medical School of Brown University, integrating his medical training with his investment expertise to identify emerging trends and opportunities in healthcare.123
Before joining Bessemer, he worked as an investment banking analyst at Goldman Sachs and as a data scientist at Kyruus, a healthcare IT startup. His investment portfolio includes notable companies such as Hinge Health, Folx Health (where he serves on the board), and Ginger, among others. Cheatham has been recognized for his contributions to the field, receiving accolades such as the Forbes 30 Under 30 award in Venture Capital and the National Venture Capital Association Rising Star Award in 2023.134
In addition to his investment role, Cheatham is involved in research and thought leadership within the healthcare space, contributing to publications and serving on the editorial team of NEJM AI. His work emphasizes the intersection of artificial intelligence and healthcare, aiming to drive innovations that improve patient outcomes and healthcare delivery systems.234
Highlights
in our latest publication in Health, Management, Policy, and Innovation – "Why AI Is Good for Our Health but May Hurt Our Wallets," we examine how current regulatory frameworks, reimbursement structures, and business models for AI in healthcare are decoupled, creating an environment in which AI may significantly increase costs without necessarily improving outcomes.
we recommend three interconnected reforms to unlock the full potential of healthcare AI: (1) rigorous pre- and post-deployment evaluation to verify proposed clinical value, (2) development of assessment standards through shared guidelines, and (3) strategic alignment of AI deployment modalities with sustainable business models – "modality-business model-market" fit
@SnehaShahJain, @drnigam, Mike Pfeffer, Linda Hoff, @Kevin_Schulman
dads will hoard youtube videos for months and force you to sit through hours of niche content any time you visit home
